Affimed to Announce Third Quarter 2024 Financial Results
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology firm based in Mannheim, Germany, is set to present its financial results for the third quarter of 2024 on an upcoming Thursday in mid-November. As a company dedicated to transforming oncology treatment, Affimed is focused on harnessing the body's immune system to combat cancer effectively.
Details About the Upcoming Conference Call
On the day of the announcement, Affimed will conduct a conference call starting at 8:30 a.m. EST / 14:30 CET. This call serves as an opportunity for stakeholders to gain insights directly from the company’s leadership regarding its financial health and strategic directions.
How to Access the Conference Call
The conference can be joined via phone or through a live audio webcast. Participants can find the webcast under the 'Webcasts' section on the Affimed investment page. This feature allows investors and interested parties to follow the discussion in real time, enhancing engagement.
Important Participation Guidelines
To ensure a smooth experience, participants are recommended to dial in 15 minutes in advance. This proactive approach helps to mitigate any technical delays, facilitating a more seamless experience during the call.
Understanding Affimed's Mission and Innovations
Affimed N.V. prides itself on providing solutions that restore patients’ natural defenses against cancerous diseases. Through their innovative technologies, particularly the innate cell engagers (ICE), the company aims to optimize the body's immune response to target and eliminate tumors effectively.
The ICE Technology and Its Impact
ICE represents a groundbreaking advancement in cancer treatment. These molecules are designed on Affimed's proprietary ROCK platform, which enables the creation of tailored molecules capable of engaging innate immune cells. This engagement is crucial for mounting an effective attack against various forms of tumors.
Current Development and Future Prospects
Several ICE candidates are currently advancing through clinical development, being assessed individually and in combination therapies. This dual approach highlights Affimed's commitment to exploring the full potential of its groundbreaking innovations.
Leadership and Vision for the Future
Affimed is spearheaded by a seasoned team of experts from the biotechnology and pharmaceutical industries, all sharing a collective vision: to ensure that cancer does not dictate the lives of patients. Their extensive experience equips them to navigate the complex landscape of cancer treatment with ingenuity and resilience.
Commitment to Transparency and Investor Relations
For stakeholders eager to learn more about Affimed's financial performance and strategic plans, the company strives to maintain transparency through regular communication. They may reach out directly to the Director of Investor Relations for further inquiries regarding the company’s performance and future initiatives.
Frequently Asked Questions
What is Affimed N.V. known for?
Affimed N.V. is a clinical-stage company focused on immuno-oncology, aiming to enhance patients' inherent ability to fight cancer using innovative therapies.
When will Affimed release its Q3 2024 financial results?
The release is scheduled for mid-November 2024, with a conference call to follow shortly after the announcement.
How can investors participate in the conference call?
Investors can participate via phone or by accessing the live audio webcast available on the Affimed investors' section of the website.
What technologies does Affimed utilize in their treatments?
Affimed utilizes innate cell engagers (ICE) generated through their proprietary ROCK platform to develop targeted cancer therapies.
Is Affimed publicly traded, and where?
Yes, Affimed N.V. is publicly traded on the Nasdaq under the ticker symbol AFMD.
